76 related articles for article (PubMed ID: 9477752)
1. [Prolonging of the follow-up intervals for non-invasive bladder tumors].
Olsen LH; Genster H
Ugeskr Laeger; 1998 Feb; 160(7):1019-21. PubMed ID: 9477752
[TBL] [Abstract][Full Text] [Related]
2. Prolonging follow-up intervals for non-invasive bladder tumors: a randomized controlled trial.
Olsen LH; Genster HG
Scand J Urol Nephrol Suppl; 1995; 172():33-6. PubMed ID: 8578253
[TBL] [Abstract][Full Text] [Related]
3. Management of low grade papillary bladder tumors.
Herr HW; Donat SM; Reuter VE
J Urol; 2007 Oct; 178(4 Pt 1):1201-5; discussion 1205. PubMed ID: 17698090
[TBL] [Abstract][Full Text] [Related]
4. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
[TBL] [Abstract][Full Text] [Related]
5. Ta T1 low and intermediate transitional cell carcinoma of the bladder: recurrence rates and the timing of check cystoscopies within the first year.
Guney S; Guney N; Canogullari Z; Ergenekon E
Urol Int; 2008; 80(2):124-8. PubMed ID: 18362479
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
Yang TB; Zeng FH; Sun ZQ
Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
[TBL] [Abstract][Full Text] [Related]
7. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
Słojewski M
Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
[TBL] [Abstract][Full Text] [Related]
8. Outcome of very large superficial bladder tumours: a 10-year experience.
Gupta SK; Parr NJ
Scand J Urol Nephrol; 2008; 42(3):243-8. PubMed ID: 18432531
[TBL] [Abstract][Full Text] [Related]
9. Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression.
Holmang S; Johansson SL
J Urol; 2002 Apr; 167(4):1634-7. PubMed ID: 11912378
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for local recurrence in patients with pTa/pT1 urinary bladder cancer.
Jancke G; Damm O; Rosell J; Jahnson S
Scand J Urol Nephrol; 2008; 42(5):417-21. PubMed ID: 18609266
[TBL] [Abstract][Full Text] [Related]
11. Transurethral treatment of invasive tumours of the urinary bladder (T1, T2): recurrence and progression.
Jacobsen F; Lundbeck F; Vaeth M; Kjaer TB
Scand J Urol Nephrol Suppl; 1987; 104():123-5. PubMed ID: 3481459
[TBL] [Abstract][Full Text] [Related]
12. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
13. [Modern follow-up strategies for the treatment of patients with superficial bladder carcinoma].
Werner W; Smesny S; Schubert J
Z Arztl Fortbild Qualitatssich; 2000 Aug; 94(6):519-27. PubMed ID: 10996943
[TBL] [Abstract][Full Text] [Related]
14. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
Raman JD; Sosa RE; Vaughan ED; Scherr DS
Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
[TBL] [Abstract][Full Text] [Related]
15. Superficial transitional cell carcinoma of the ureteral orifice: higher risk of developing subsequent upper urinary tract tumors.
Chou EC; Lin AT; Chen KK; Chang LS
Int J Urol; 2006 Jun; 13(6):682-5. PubMed ID: 16834642
[TBL] [Abstract][Full Text] [Related]
16. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years.
Serretta V; Pavone C; Ingargiola GB; Daricello G; Allegro R; Pavone-Macaluso M
Eur Urol; 2004 Jun; 45(6):730-5; discussion 735-6. PubMed ID: 15149744
[TBL] [Abstract][Full Text] [Related]
17. Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors.
Palou J; Rodríguez-Rubio F; Millán F; Algaba F; Rodríguez-Faba O; Huguet J; Villavicencio H
Urology; 2009 Jun; 73(6):1313-7. PubMed ID: 19362341
[TBL] [Abstract][Full Text] [Related]
18. Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer.
Gårdmark T; Jahnson S; Wahlquist R; Wijkström H; Malmström PU
BJU Int; 2007 Apr; 99(4):817-20. PubMed ID: 17244282
[TBL] [Abstract][Full Text] [Related]
19. Watchful waiting policy in recurrent Ta G1 bladder tumors.
Gofrit ON; Pode D; Lazar A; Katz R; Shapiro A
Eur Urol; 2006 Feb; 49(2):303-6; discussion 306-7. PubMed ID: 16413659
[TBL] [Abstract][Full Text] [Related]
20. The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour.
Kompier LC; van der Aa MN; Lurkin I; Vermeij M; Kirkels WJ; Bangma CH; van der Kwast TH; Zwarthoff EC
J Pathol; 2009 May; 218(1):104-12. PubMed ID: 19156776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
